US-based Curis has signed a collaboration agreement with Indian drug-maker Dr. Reddy’s Laboratories subsidiary Aurigene Discovery Technologies to discover, develop and commercialise small molecule antagonists for immuno-oncology and selected precision oncology targets.
Curis holds the option to exclusively license compounds once a development candidate is nominated within each respective programme, and the collaboration allows for the inclusion of multiple programmes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Curis president Ali Fattaey said: "The multi-year nature of our collaboration means that the parties have the potential to generate a steady pipeline of novel drug candidates in the coming years.
"Addressing immune checkpoint pathways is now a well validated strategy to treat human cancers and the ability to target PD-1/PD-L1 and other immune checkpoints with orally available small molecule drugs has the potential to be a distinct and major advancement for patients."
As part of the deal, Aurigene will take responsibility for all discovery and preclinical activities, including IND-enabling studies and providing Phase I clinical trial supply. Curis will be responsible for all clinical development, regulatory and commercialisation efforts worldwide, excluding India and Russia.
The first two programmes will be an orally-available small molecule antagonist of programmed death ligand-1 (PD-L1) in the immuno-oncology field, and an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCuris issued 17.1 million shares of its common stock to Aurigene, which are subject to a lock-up agreement until 18 January 2017.
With the option for Curis to extend the broad immuno-oncology exclusivity, the deal provides an opportunity for the parties to collaborate exclusively in immuno-oncology for an initial period of two years.
For the first two programmes, Curis agreed to pay $52.5m per programme, while for the third and fourth programmes, up to $50m per programme, and for any programme thereafter, up to $140.5m per programme.
